Mass spectrometric determination of fatty acids

Patent metadata

Field	Value
Publication number	US-10242852-B2
Application number	US-201615233322-A
Country	US
Kind code	B2
Filing date	Aug 10, 2016
Priority date	Jun 22, 2011
Publication date	Mar 26, 2019
Grant date	Mar 26, 2019

Abstract

The invention relates to the detection of fatty acids. In a particular aspect, the invention relates to methods for detecting very long chain fatty acids and branched chain fatty acids by mass spectrometry.

First claim

That which is claimed is:

1. A method for determining an amount of one or more very long chain fatty acids (VLCFA) and/or branched chain fatty acids (BCFA) in a sample by mass spectrometry, the method comprising:
(a) subjecting the sample containing an amount of VLCFA and/or BCFA to an ionization source to generate one or more VLCFA and/or BCFA ions detectable by mass spectrometry, wherein said one or more ions comprise ions with a mass to charge ratio (m/z) selected from 339.3±0.5, 367.3±0.5, 395.4±0.5, 297.3±0.5, and 311.2±0.5;
(b) determining the amount of the one or more VLCFA and/or BCFA ions by mass spectrometry; and
(c) determining the amount of the VLCFA and/or BCFA in the sample from the amount of the one or more VLCFA and/or BCFA ions determined in step (b).

2. The method of claim 1 , wherein said one or more VLCFA are selected from the group consisting of docosanoic acid, tetracosanoic acid, and hexacosanoic acid.

3. The method of claim 1 , wherein said one or more BCFA are selected from the group consisting of pristanic acid and phytanic acid.

4. The method of claim 1 , wherein said ionization source is in negative ionization mode.

5. The method of claim 1 , wherein the ionization source is electron ionization, chemical ionization, electrospray ionization (ESI), photon ionization, photoionization, atmospheric pressure photoionization (APPI), laser diode thermal desorption (LDTD), fast atom bombardment (FAB), liquid secondary ionization (LSI), matrix assisted laser desorption ionization (MALDI), field ionization, field desorption, thermospray ionization, plasmaspray ionization, surface enhanced laser desorption ionization (SELDI), inductively coupled plasma (ICP), or particle beam ionization.

6. The method of claim 1 , wherein the amounts of one or more VLCFA and one or more BCFA are separately determined.

7. The method of claim 6 , wherein said one or more VLCFA are selected from the group consisting of docosanoic acid, tetracosanoic acid, and hexacosanoic acid, and wherein said one or more BCFA are selected from the group consisting of pristanic acid and phytanic acid.

8. The method of claim 1 , wherein said sample comprises a human sample comprising plasma or serum.

9. The method of claim 1 , wherein said sample is subjected to a hydrolyzing agent prior to ionization.

10. The method of claim 1 , wherein the sample is subjected to liquid/liquid extraction prior to ionization.

11. The method of claim 1 , wherein the one or more VLCFA and/or BCFA are subjected to a liquid chromatography column prior to ionization.

12. The method of claim 11 , wherein the liquid chromatography column comprises a high performance liquid chromatography (HPLC), reverse phase liquid chromatography (RPLC), turbulent flow liquid chromatography (TFLC), or high turbulence liquid chromatography (HTLC).

13. The method of claim 1 , wherein the method further comprises determining the amount of the one or more internal standards.

14. The method of claim 13 , wherein the internal standard is pristanic acid- 2 H 3 phytanic acid- 2 H 3 , docosanoic acid- 2 H 3 , tetracosanoic acid- 2 H 3 , or hexacosanoic acid- 2 H 3 .

15. A method of diagnosing or monitoring a peroxisomal disorder comprising determining an amount of one or more very long chain fatty acids (VLCFA) and/or branched chain fatty acids (BCFA) in a patient sample by steps of claim 1 .

16. The method of claim 1 , wherein the peroxisomal disorder is Zellweger syndrome, pseudo-Zellweger syndrome, infantile and adult Refsum disease, adrenoleukodystrophy, rhizomelic chondrodysplasia punctata type 1 (RCDP-1), D-bifunctional protein deficiency, or acyl-coA oxidase deficiency.

17. A method for determining an amount of one or more very long chain fatty acids (VLCFA) and/or branched chain fatty acids (BCFA) in a sample by mass spectrometry, the method comprising:
(a) subjecting the sample containing an amount of VLCFA and/or BCFA to a hexane extraction;
(b) subjecting the sample to liquid chromatography;
(c) subjecting the sample to an ionization source to generate one or more VLCFA and/or BCFA ions detectable by mass spectrometry, wherein said one or more ions comprise ions with a mass to charge ratio (m/z) selected from 339.3±0.5, 367.3±0.5, 395.4±0.5, 297.3±0.5, and 311.2±0.5;
(d) determining the amount of the one or more VLCFA and/or BCFA ions by mass spectrometry; and
(e) determining the amount of the VLCFA and/or BCFA in the sample from the amount of the one or more VLCFA and/or BCFA ions determined in step (d).

18. The method of claim 17 , wherein said one or more VLCFA are selected from the group consisting of docosanoic acid, tetracosanoic acid, and hexacosanoic acid.

19. The method of claim 17 , wherein said one or more BCFA are selected from the group consisting of pristanic acid and phytanic acid.

20. The method of claim 17 , wherein the amounts of one or more VLCFA and one or more BCFA are separately determined.

21. The method of claim 17 , wherein the ionization source is electron ionization, chemical ionization, electrospray ionization (ESI), photon ionization, photoionization, atmospheric pressure photoionization (APPI), laser diode thermal desorption (LDTD), fast atom bombardment (FAB), liquid secondary ionization (LSI), matrix assisted laser desorption ionization (MALDI), field ionization, field desorption, thermospray ionization, plasmaspray ionization, surface enhanced laser desorption ionization (SELDI), inductively coupled plasma (ICP), or particle beam ionization.

22. The method of claim 17 , wherein said sample comprises a human sample comprising plasma or serum.

23. The method of claim 17 , wherein said sample is subjected to an acid hydrolysis prior to ionization.

24. The method of claim 17 , wherein the method further comprises determining the amount of the one or more internal standards.

25. The method of claim 24 , wherein the internal standard is pristanic acid- 2 H 3 phytanic acid- 2 H 3 , docosanoic acid- 2 H 3 , tetracosanoic acid- 2 H 3 , or hexacosanoic acid- 2 H 3 .

26. A method of diagnosing or monitoring a peroxisomal disorder comprising determining an amount of one or more very long chain fatty acids (VLCFA) and/or branched chain fatty acids (BCFA) in a patient sample by steps of claim 17 .

27. The method of claim 26 , wherein the peroxisomal disorder is Zellweger syndrome, pseudo-Zellweger syndrome, infantile and adult Refsum disease, adrenoleukodystrophy, rhizomelic chondrodysplasia punctata type 1 (RCDP-1), D-bifunctional protein deficiency, or acyl-coA oxidase deficiency.

28. The method of claim 17 , wherein said ionization source is in negative ionization mode.

Assignees

• Quest Diagnostics Invest Inc

Inventors

• Goldman Scott

Classifications

• G01N2560/00

  Chemical aspects of mass spectrometric analysis of biological material · CPC title

• Y10T436/200833

  Carbonyl, ether, aldehyde or ketone containing · CPC title

• H01J49/0036 Primary

  Step by step routines describing the handling of the data generated during a measurement · CPC title

• H01J49/0027

  Methods for using particle spectrometers · CPC title

• H01J49/10

  Ion sources; Ion guns · CPC title